Cytochrome P450 (CYP) is a critical drug-metabolizing enzyme superfamily. Modulation of CYP enzyme activities has the potential to cause drug–drug/herb interactions. Drug–drug/herb interactions can lead to serious adverse drug reactions (ADRs) or drug failures. Therefore, there is a need to examine the modulatory effects of new drug entities or herbal preparations on a wide range of CYP isoforms. The classic method of quantifying CYP enzyme activities is based on high-performance liquid chromatography (HPLC), which is time- and reagent-consuming. In the past two decades, high-throughput screening methods including fluorescence-based, luminescence-based, and mass-spectrometry-based assays have been developed and widely applied to estimate CYP enzyme activities. In general, these methods are faster and use lower volume of reagents than HPLC. However, each high-throughput method has its own limitations. Investigators may make a selection of these methods based on the available equipment in the laboratory, budget, and enzyme sources supplied. Furthermore, the current high-throughput systems should look into developing a reliable automation mechanism to accomplish ultra-high-throughput screening in the near future.
13 February 2020 in Human & Experimental Toxicology
Cytochrome P450 4B1 (CYP4B1) plays crucial roles in biotransforming of xenobiotics. Its predominant extrahepatic expression has been associated with certain tissue-specific toxicities. However, the expressions of CYP4B1 in various cancers and hence their potential roles in cancer development were inclusive. In this work, existing knowledge on expression and regulation of CYP4B1 gene and protein, catalysis of CYP4B1, association of CYP4B1 with cancers, contradicting findings about human CYP4B1 activities as well as the employing CYP4B1 in suicide gene approach for cancer treatment were reviewed. To date, it appears that there is a wide spectrum of tissue distribution of CYP4B1 with lungs as the predominant sites. Several nuclear receptors are possibly responsible for regulating its gene expression. The involvement of CYP4B1 in cancer was considered via activation of procarcinogens and neovascularization. However, human CYP4B1 was found to be inactive due to a substitution of proline with serine at position 427. Suicide gene approach combining reengineered CYP4B1 and prodrug 4-ipomeanol (4-IPO) has shown a promising potential for targeted cancer therapy. Further studies should focus on the verification of human CYP4B1 catalytic activities. More compounds with similar structure as 4-IPO should be tested to identify more alternative agents for the suicide gene approach in cancer treatment.
Dengue has become a global affliction despite continuous efforts to find cure for this age-old disease. Hopeful results for dengue vaccine are far-fetched as the effectiveness are tied to previous dengue virus (DENV) exposure and billions of dollars needed to be invested for vaccine development. Medicinal plants are ideal alternatives to combat DENV infection as it has long been utilized in traditional medicine besides showing virucidal properties. However, the mechanism of action by which the plant compounds inhibits the viral replication machinery remains to be discovered. This review provides existing knowledge on how DENV replicates within the host cells, recruiting more than 70 medicinal plants and some essential oils with anti-DENV properties, highlighting possible viral targets for DENV inhibition. The possible mechanism on how phytochemicals modulates host immune system in DENV infection by inhibiting cytokine storm and vascular leakage, were also discussed. Based on the in silico findings, NS2B/NS3 protease is the most distinctive DENV inhibitor target. Most anti-DENV plants research stood at their initial stages and efforts should be channeled into further in vitro characterization, in vivo studies by employing larger subsets of human subjects, and in silico studies to facilitate the understanding of inhibition mechanism.